Zydus Lifesciences Expands Access to Oncology by Introducing the World’s First Nivolumab Biosimilar in India
Zydus Lifesciences Limited announced the launch of Tishtha™, the world’s first biosimilar for the cancer immunotherapy drug Nivolumab, in India on January 22, 2026. This is targeted at dramatically improving access to advanced oncology treatments by making the therapy available at approximately one-fourth the cost of the reference drug. The…
India’s Coal Growth Is Delayed as Renewables Grow, Reflecting the World’s Energy Transition
The ambitious target of coal-fired power projects in India is running into operational and investment challenges, with only a small portion of the projects being realized. This is being faced at a time when renewable energy sources, especially solar energy, appear to be rapidly increasing in power generation, enough to…
India Eyes Global Green Hydrogen Hub: 5 MT Target by 2030
Union Minister Pralhad Joshi declared that the target for green hydrogen is 5 million metric tons per year by 2030. He stated that the country’s aggressive transition into renewable energy sources, started by Prime Minister Modi, is not a burden but the main engine of economic growth and has successfully…
JSW Infra: Motilal Oswal Starts Purchasing, Aiming for Rs 360
Motilal Oswal has issued another research report, re-emphasizing the ‘BUY’ rating for JSW Infrastructure, with a target price of INR 360. The brokerage house pointed out the 14% YoY increase in revenues to INR 13.5 billion, along with 8% increase in the volume of cargoes handled at 31.7 million tons…
